Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

General Research Article

Moxifloxacin-Loaded Lipidic Nanoparticles for Antimicrobial Efficacy

Author(s): Mohammad Darvishi*, Shahrzad Farahani and Azadeh Haeri

Volume 27 , Issue 1 , 2021

Published on: 01 July, 2020

Page: [135 - 140] Pages: 6

DOI: 10.2174/1381612826666200701152618

Price: $65

Abstract

Background: Pulmonary infections are an increasing problem in individuals and current therapies are lacking. Liposomes are spherical lipidic vesicles composed of phospholipid and cholesterol. Liposomes have numerous advantages, such as biodegradability, biocompatibility, non-immunogenicity, lack of toxicity, controlled release properties and high stability.

Objective: This work was carried out to construct a novel liposomal moxifloxacin formulation and examine its antimicrobial effects against Pseudomonas aeruginosa and Staphylococcus aureus.

Methods: The liposomal moxifloxacin formulation was prepared by the thin-film hydration method. The bilayer was composed of cholesterol and phospholipid at 30:70 molar ratio. To prepare cationic liposomes, 5% cationic agent (CTAB) was added. The liposomes were reduced in size with the bath sonication technique. The liposomal characterizations were tested regarding vesicle size, surface charge and drug encapsulation efficacy. Microdilution method was used to determine the Minimum Inhibitory Concentration (MIC) against Pseudomonas aeruginosa and Staphylococcus aureus of the free drug, neutral and cationic moxifloxacin liposomes.

Results: The size of the liposomes was 50-70 nm. The zeta potential of neutral and cationic vesicles was ∼0 and +22 mV. The MIC values against Pseudomonas aeruginosa of the free drug, neutral and cationic moxifloxacin liposomes were 10, 5 and 2.5, respectively. The MICs against Staphylococcus aureus of the free drug, neutral and cationic moxifloxacin liposomes were 1, 1 and 0.5, respectively.

Conclusion: This study demonstrates that the encapsulation of moxifloxacin into liposomes (especially cationic vesicles) could enhance antimicrobial properties.

Keywords: Nanoliposomes, moxifloxacin, antimicrobial effect, infection, liposomes, Minimum Inhibitory Concentration (MIC).

[1]
Grossman RF, Hsueh P-R, Gillespie SH, Blasi F. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 2014; 18: 14-21.
[http://dx.doi.org/10.1016/j.ijid.2013.09.013] [PMID: 24211230]
[2]
Berkowitz AC, Goddard DM. Novel drug delivery systems: future directions. J Neurosci Nurs 2009; 41(2): 115-20.
[http://dx.doi.org/10.1097/JNN.0b013e318193458b] [PMID: 19361127]
[3]
Mozafari M. Nanoliposomes: preparation and analysis Liposomes. Springer 2010; pp. 29-50.
[http://dx.doi.org/10.1007/978-1-60327-360-2_2]
[4]
Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65(1): 36-48.
[http://dx.doi.org/10.1016/j.addr.2012.09.037] [PMID: 23036225]
[5]
Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 2003; 89(3): 237-49.
[http://dx.doi.org/10.1177/030089160308900302] [PMID: 12908776]
[6]
Elizondo E, Moreno E, Cabrera I, et al. Liposomes and other vesicular systems: structural characteristics, methods of preparation, and use in nanomedicine Progress in molecular biology and translational science 104. Elsevier 2011; pp. 1-52.
[http://dx.doi.org/10.1016/B978-0-12-416020-0.00001-2]
[7]
Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008; 9(10): 1755-72.
[http://dx.doi.org/10.1517/14656566.9.10.1755] [PMID: 18570608]
[8]
Al Omari MM, Jaafari DS, Al-Sou’od KA, Badwan AA. Moxifloxacin hydrochloride profiles of drug substances, excipients and related methodology 39. Elsevier 2014; pp. 299-431.
[9]
Zhang G, Zou J, Liu F, et al. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res 2013; 46(7): 607-13.
[http://dx.doi.org/10.1590/1414-431X20132817] [PMID: 23903685]
[10]
Hope MJ, Kitson CN. Liposomes. A perspective for dermatologists. Dermatol Clin 1993; 11(1): 143-54.
[http://dx.doi.org/10.1016/S0733-8635(18)30291-2] [PMID: 8435909]
[11]
Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 381-91.
[http://dx.doi.org/10.3109/21691401.2014.953633] [PMID: 25222036]
[12]
Margalit R. Liposome-mediated drug targeting in topical and regional therapies. Critical Reviews™ in Therapeutic Drug Carrier Systems 1995; 12(2-3)
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.30]
[13]
Gharib A, Faezizadeh Z, Godarzee M. Therapeutic efficacy of epigallocatechin gallate-loaded nanoliposomes against burn wound infection by methicillin-resistant Staphylococcus aureus. Skin Pharmacol Physiol 2013; 26(2): 68-75.
[http://dx.doi.org/10.1159/000345761] [PMID: 23296023]
[14]
Ruopp M, Chiswell K, Thaden JT, Merchant K, Tsalik EL. Respiratory tract infection clinical trials from 2007 to 2012. A systematic review of clinicaltrials. gov. Ann Am Thorac Soc 2015; 12(12): 1852-63.
[http://dx.doi.org/10.1513/AnnalsATS.201505-291OC] [PMID: 26360527]
[15]
Anderson EJ. Respiratory infections Infectious Complications in Cancer Patients. Springer 2014; pp. 203-36.
[http://dx.doi.org/10.1007/978-3-319-04220-6_7]
[16]
Andrade F, Rafael D, Videira M, Ferreira D, Sosnik A, Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev 2013; 65(13-14): 1816-27.
[http://dx.doi.org/10.1016/j.addr.2013.07.020] [PMID: 23932923]
[17]
Sempkowski M, Locke T, Stras S, Zhu C, Sofou S. Liposome-based approaches for delivery of mainstream chemotherapeutics: preparation methods, liposome designs, therapeutic efficacy. Critical Reviews™ in Oncogenesis 2014; 19(3-4)
[http://dx.doi.org/10.1615/CritRevOncog.2014011533]
[18]
Madni A, Sarfraz M, Rehman M, et al. Liposomal drug delivery: a versatile platform for challenging clinical applications. J Pharm Pharm Sci 2014; 17(3): 401-26.
[http://dx.doi.org/10.18433/J3CP55] [PMID: 25224351]
[19]
Eloy JO, Petrilli R, Trevizan LNF, Chorilli M. Immunoliposomes: A review on functionalization strategies and targets for drug delivery. Colloids Surf B Biointerfaces 2017; 159: 454-67.
[http://dx.doi.org/10.1016/j.colsurfb.2017.07.085] [PMID: 28837895]
[20]
Sousa J, Alves G, Fortuna A, Falcão A. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf 2014; 9(2): 89-105.
[http://dx.doi.org/10.2174/1574886308666140106154754] [PMID: 24410307]
[21]
Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release 2014; 190: 15-28.
[http://dx.doi.org/10.1016/j.jconrel.2014.03.053] [PMID: 24747160]
[22]
Meng E, Hoang T. Micro- and nano-fabricated implantable drug-delivery systems. Ther Deliv 2012; 3(12): 1457-67.
[http://dx.doi.org/10.4155/tde.12.132] [PMID: 23323562]
[23]
Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s principles of internal medicine. McGraw-Hill Professional Publishing 2018.
[24]
Kaskoos RA. Investigation of moxifloxacin loaded chitosan-dextran nanoparticles for topical instillation into eye: In-vitro and ex-vivo evaluation. Int J Pharm Investig 2014; 4(4): 164-73.
[http://dx.doi.org/10.4103/2230-973X.143114] [PMID: 25426437]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy